# US 2023/0398065 A1 · Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398065 A1
- Document ID: US20230398065A1
- Status: Published application
- Kind: A1
- Application number: 18/333,095
- Filed: 2023-06-12
- Published: 2023-12-14
- Earliest claimed: 2017-09-27
- Applicants: Novaliq GmbH
- Inventors: Bernhard GÜNTHER; Frank LÖSCHER; Kirsten EICKHOFF
- Web page: https://patentgrep.com/patent/US20230398065A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 μg.

## Claims

### Claim 1

A pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein
the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and
the composition is administered to the eye of a subject; and
the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 μg.

### Claim 2 (depends on 1)

The composition for the use according to claim 1, wherein the semifluorinated alkane is selected from F6H8 and F4H5, preferably wherein the semifluorinated alkane is F6H8.

### Claim 3 (depends on 1, 2)

The composition for use according to claim 1 or 2, wherein the composition is administered topically to the eye of a subject.

### Claim 4

The composition for use according to any one of the preceding claims, wherein the composition further comprises a solubilising agent.

### Claim 5 (depends on 4)

The composition for use according to claim 4, wherein solubilising agent is selected from ethanol, medium chain triglycerides (MCT) and diethylene glycol monoethyl ether (DEGEE).

### Claim 6 (depends on 4, 5)

The composition for use according to claim 4 or 5, wherein the solubilising agent is comprised in an amount of up to 2.5% (w/w) with respect to the total weight of the liquid vehicle.

### Claim 7 (depends on 4, 5, 6)

The composition for use according to any one of claims 4 to 6, wherein the solubilising agent is ethanol.

### Claim 8

The composition for use according to any one of the preceding claims, wherein the composition is substantially free of water and of a preservative.

### Claim 9

The composition for use according to any one of the preceding claims, wherein the composition target dose volume per eye is from about 8 to 15 μl, preferably from about 10 to 12 μl.

### Claim 10

The composition for use according to any one of the preceding claims, wherein the composition comprises about 0.005 to 0.015% (w/v), preferably about 0.008 to 0.012% (w/v) latanoprost.

### Claim 11

The composition for use according to any one of the preceding claims, wherein the amount of latanoprost administered in a single dose per eye is in the range of from about 1.0 to 1.2 μg.

### Claim 12

The composition for use according to any one of the preceding claims, wherein the composition comprises about 0.01% (w/v) latanoprost, and wherein the latanoprost administered in a single dose per eye is about 1.1 μg and wherein the composition target dose volume per eye is about 11 μl.

### Claim 13

The pharmaceutical composition for use according to any one of the preceding claims, wherein the composition comprises latanoprost dissolved in a liquid vehicle essentially consisting of at least 99% (w/w) of 1-perfluorobutyl-pentane (CF3(CF2)3—(CH2)4CH3 (F4H5)) or 1-perfluorohexyl-octane (CF3(CF2)5—(CH2)7CH3 (F6H8)) and up to 1% (w/w) ethanol, with respect to the total weight of the liquid vehicle.

### Claim 14

The composition for use according to any one of the preceding claims, wherein the composition is administered once daily.

### Claim 15

A kit comprising a pharmaceutical composition for use according to any one of the preceding claims, wherein the kit comprises a container for holding the pharmaceutical composition and a drop dispenser for administering the composition.
